

26<sup>th</sup> March 2007

**Topical Issues with Drug Eluting Stents**  
**Roundtable Meeting Monday 26<sup>th</sup> March 2007, 12.00 – 2.00pm**  
**Lafourche Room, Loews Hotel, New Orleans, USA**

**Co-chairs: Steven Steinhubl, USA and Sigmund Silber, Germany**

12.00 – 12.30pm	Lunch	
12.30 – 12.35pm	<b>Introduction</b>	<i>Co-chairs</i>
12.35 – 12.55pm	<b>Drug Eluting Stents (DES): Review of the ongoing debate</b>	<i>J. Popma</i>
12.55 – 1.25pm	<b>Group Discussion:</b>	<i>All</i>
	<b>Impact on DES utilization</b>	
	<ul style="list-style-type: none"><li>• What impact has been felt in clinical practice patterns on the use of DES in the US?</li><li>• Are DES being used more selectively now? And if so, in what types of patients?</li><li>• Is there an increase in use of Bare Metal Stents (BMS) as a result of these issues?</li><li>• What is the impact on DES use in Europe?</li></ul>	
1.25 – 1.55pm	<b>Impact on prescribing patterns and the use of antiplatelet therapies in patients receiving DES</b>	<i>All</i>
	<ul style="list-style-type: none"><li>• Is late stent thrombosis perceived as an antiplatelet therapy issue or a DES issue?</li><li>• Dual antiplatelet therapy after DES: what is the optimal duration of therapy?</li><li>• In which patients should dual antiplatelet therapy be extended beyond 12 months?</li></ul>	
	<b>Potential Additional Questions:</b>	
	<ul style="list-style-type: none"><li>• Should tests for drug responsiveness be used? Which ones, when, and, in which patients?</li><li>• What antiplatelet therapy should be considered in PAD patients with DES after 12 months?</li></ul>	
1.55 – 2.00pm	<b>Concluding Remarks</b>	<i>Co-chairs</i>